PFI AND A&S SIGN ASPIRIN DEAL

EDISON, N.J. -- Pharmaceutical Formulations Inc. here, the second-largest maker of solid-dosage generic pharmaceuticals in the country, has entered an agreement with A&S Pharmaceutical Corp., Bridgeport, Conn., to sell and market A&S's 325-mg aspirin. A&S is the second-largest manufacturer of private-label aspirin in the United States. Charles E. LaRosa, PFI's president and chief executive officer,

EDISON, N.J. -- Pharmaceutical Formulations Inc. here, the second-largest maker of solid-dosage generic pharmaceuticals in the country, has entered an agreement with A&S Pharmaceutical Corp., Bridgeport, Conn., to sell and market A&S's 325-mg aspirin. A&S is the second-largest manufacturer of private-label aspirin in the United States. Charles E. LaRosa, PFI's president and chief executive officer, said in a prepared statement that "this agreement is expected to add over $5 million in incremental revenue and important cash flow for fiscal 1998, while allowing our company to provide competitive pricing to our customers." The agreement also allows PFI to expand its aspirin offerings at a time when sales in the analgesic category are being driven by aspirin's perceived heart-maintenance benefits, according to LaRosa.